This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Anthony S. Robbins, MD, MPH
San Antonio, Tex

JAMA. 1994;271(3):192.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Catalona et al¹ express proper caution regarding the value of prostate-specific antigen (PSA) screening in the general population, noting that its benefits in reducing mortality have not been established. However, their findings can actually be used to estimate the possible adverse mortality associated with PSA screening and its sequelae among men 75 years of age and older.

Recently, Fleming et al² demonstrated by use of decision analysis that, compared with watchful waiting, radical prostatectomy in men 70 years of age and older with localized prostate cancer not only lacks treatment superiority, but generally appears to be harmful. This is due to two facts: first, it has yet to be demonstrated that among clinically localized cases, mortality from prostate cancer is reduced after radical prostatectomy compared with mortality among cases not treated surgically; and second, in men 75 years of age and older, the 30-day postoperative . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?